• 2'3'-cGAMP: STING Assay Workflows

  2026-08-12

  Build cleaner cGAS-STING experiments with 2'3'-cGAMP (sodium salt) as a defined downstream STING control, rather than relying only on variable DNA-sensing stimuli. The workflow connects pathway activation, type I interferon induction, PD-L1 biology, and TOP1-linked cancer research while addressing solubility, uptake, timing, and assay-specific troubleshooting.

• TSPAN18–STIM1 Axis in Prostate Cancer Bone Metastasis

  2026-08-12

  Zhou et al. identified TSPAN18 as a binding partner that protects STIM1 from TRIM32-mediated ubiquitination and degradation, thereby amplifying store-operated calcium entry in prostate cancer cells. The study connects this post-translational mechanism to migration, invasion, bone metastasis, and adverse clinical features, while positioning TSPAN18 as a candidate target for mechanistic prostate cancer research.

• Calpain Inhibitor I, ALLN: Practical Workflow Guide

  2026-08-11

  Calpain Inhibitor I, ALLN (SKU A2602) is a research inhibitor for calpain I, calpain II, and selected cathepsins, supporting controlled protease perturbation in apoptosis, inflammation, and ischemia-reperfusion workflows. This guide covers preparation, controls, assay setup, and interpretation while emphasizing that the compound is not intended for diagnostic, clinical, or therapeutic use.

• Kupffer Cell Plasticity in Liver Metastasis

  2026-08-11

  The reference study shows that liver metastasis-associated macrophages are maintained through more than simple replacement of Kupffer cells by recruited monocytes. By combining lineage tracing, proliferation recording, flow cytometry, and CITE-seq, the authors identify compensatory local proliferation and infiltration of reprogrammed Kupffer cells as parallel sources of immunosuppressive macrophages.

• MK-5108: Precision Aurora A Assay Strategy

  2026-08-10

  MK-5108 (VX-689) is a highly selective Aurora A inhibitor for dissecting mitotic control and tumor cell proliferation. This article translates retinoblastoma evidence into practical assay-design decisions, emphasizing target validation, selectivity, and xenograft interpretation.

• ddhCTP Assays: From Chain Termination to Insight

  2026-08-09

  Explore how ddhCTP, or 3ʹ-deoxy-3′,4′-didehydro-CTP, can distinguish direct viral polymerase inhibition from broader viperin-mediated antiviral mechanisms. This evidence-led guide translates recent coronavirus findings into practical assay decisions for flavivirus and RNA virus research.

• MnTBAP Chloride: Designing Mitochondrial Redox Assays

  2026-08-08

  MnTBAP Chloride is a cell-permeable SOD mimetic for investigating mitochondrial superoxide, inflammation, and redox signaling. This guide translates chronic-stress findings into a practical assay framework for separating antioxidant rescue from broader behavioral and inflammatory effects.

• Viperin Targets nsp8 to Block Coronavirus Replication

  2026-08-07

  The reference study identifies a ddhCTP-independent antiviral mechanism in which viperin binds coronavirus nsp8 and disrupts replication-transcription complex assembly and RNA-dependent RNA polymerase activity. Using porcine deltacoronavirus as a model, the authors map the interaction to viperin residues 43–184 and nsp8 K82, providing a mechanistic framework for evaluating conserved anti-coronavirus targets.

• Tubastatin A: HDAC6 Inhibitor Workflows for Myocardial Prote

  2026-08-07

  Tubastatin A stands apart as a highly selective HDAC6 inhibitor, unlocking new experimental avenues in myocardial injury, neuroprotection, and inflammation research. This guide delivers actionable protocols, troubleshooting strategies, and comparative insights grounded in the latest translational breakthroughs.

• Nuclear cGAS Suppresses L1 Retrotransposition via CHK2-TRIM4

  2026-08-06

  This study uncovers a novel genome-protective function for nuclear cGAS in human cells, revealing that it restricts LINE-1 retrotransposition through a CHK2-dependent TRIM41-ORF2p degradation pathway. The findings clarify a key posttranslational regulatory mechanism and have implications for aging, genome stability, and cancer research.

• Tumor-Targeted PAD4 Inhibitors Block NET-Mediated Metastasis

  2026-08-06

  This study introduces phenylboronic acid (PBA)-modified PAD4 inhibitors that selectively target tumor cells and neutrophils, blocking the PAD4-H3cit-NETs pathway linked to tumor growth and metastasis. The findings highlight a new approach to cancer therapy by combining molecular targeting with immune microenvironment modulation.

• Dihydroartemisinin: Precision Applications and mTOR Pathway

  2026-08-05

  Explore the advanced scientific landscape of Dihydroartemisinin, a potent Artemisia plant extract, focusing on its precision use as an mTOR signaling pathway inhibitor and in antimalarial research. This article uniquely bridges molecular mechanisms with protocol optimization, offering deeper guidance for translational research teams.

• Flexible Phage Nanofibers Enhance Capture of Rare Circulatin

  2026-08-05

  This study introduces a novel approach using flexible M13 phage nanofibers, engineered with cell-specific aptamers and tethered to magnetic beads, to selectively isolate and subtype rare circulating tumor cells (CTCs) from whole blood. The work demonstrates substantial improvements in both target-cell capture efficiency and anti-fouling properties, providing a significant advance for liquid biopsy and cancer diagnostics.

• Polymeric Nanoplatforms Enhance cGAS-STING in Macrophages fo

  2026-08-04

  The referenced study introduces a mannose-modified, pH-responsive polymeric nanoplatform co-delivering R848 and 2'3'-cGAMP to reprogram tumor-associated macrophages and enhance antitumor responses. This approach downregulates SIRPα in macrophages via STING activation, potentiates phagocytosis, and synergizes with immune checkpoint blockade, offering a multifaceted strategy for cancer immunotherapy.

• Strategic Antioxidant Screening: DPPH and Translational Inno

  2026-08-04

  This thought-leadership article explores how DPPH (2,2-Diphenyl-1-Picrylhydrazyl) Radical underpins translational antioxidant research, integrating mechanistic insights with actionable guidance. Drawing on comparative metabolomics of Taihangia rupestris, it positions APExBIO’s DPPH as an essential tool for high-throughput screening and sustainable drug discovery, and provides strategic recommendations for protocol optimization and future-ready translational workflows.

15235 records 1/1016 page Next 12345 下5页 Last page